With over 20 years of experience in clinical research, scaling organizations, M&As and turning around site performance, Radoslaw Janiak MBA, MD understands the nuances of site operations, effective patient engagement strategies and protecting study timelines.
Dr Janiak oversaw over 70 studies as a Principal and Co-Investigator at one of the first Dedicated Research Sites in Poland, which he established in 2003. After an M&A in 2006, he joined Synexus, where he later supervised operations of 160 sites in Europe, Africa, India and the US as Executive VP and COO. He closed his Synexus chapter as President and COO.
In October 2019, he co-founded FutureMeds and became the CEO of the new independent, fully dedicated Research Site Network in Europe. FutureMeds now has dedicated sites operating in 6 countries, and its DCT solution is available in 18 European countries.
